Saturday 17 October 2026
Export LUCD’s income statement to Excel — free account
Lucid Diagnostics Inc.
LUCD Healthcare Medical Devices
Lucid Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 26.7%, EPS was flat, free cash flow fell 7.04% and total debt fell 7.11%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.48
0.04
−7.69%
Follow LUCD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
24.84 | 23.61 | 31.38 | 35.99 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.03) | (8.83) | (13.31) | (17.34) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 17.93 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 18.11 | |
EV/Sales |
19.15 | 21.34 | 30.86 | 34.17 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.92) | (2.16) | (3.44) | (3.97) | |
EV/FCF |
(1.91) | (2.15) | (3.41) | (3.94) | |
Quick Ratio |
1.83 | 1.24 | 0.97 | 1.25 | |
Current Ratio |
1.90 | 1.31 | 1.07 | 1.33 | |
Net Debt/EBITDA |
2.17 | 0.78 | 0.23 | 0.79 | |
Debt/Assets |
41.92% | 59.34% | 73.94% | 60.34% | |
Debt/Equity |
0.86 | 2.19 | 6.30 | 2.15 | |
Asset Turnover |
0.12 | 0.13 | 0.15 | 0.14 | |
Operating CF/Net income |
1.05 | 0.77 | 0.51 | 0.77 | |
Capex/Depreciation |
(0.13) | (0.24) | (0.97) | (0.09) | |
Interest Coverage |
(5,879.50) | (2,802.00) | (2,019.00) | (3,200.25) | |
Research and Development Expense of Revenue |
105.04% | 114.56% | 96.02% | 80.87% | |
Selling, General and Administrative Expense of Revenue |
817.18% | 786.30% | 830.73% | 782.43% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
95.13% | 77.46% | 112.34% | 114.86% | |
Graham Net Nets |
0.21 | 0.07 | 0.01 | 0.04 | |
Graham Number |
2.48 | 3.03 | 0.68 | 0.00 | |
Earnings Yield |
(102.97%) | (88.07%) | (40.87%) | (43.93%) | |
Free Cash Flow Yield |
(40.44%) | (42.01%) | (28.82%) | (24.08%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.10) | (0.12) | (0.09) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.12) | (0.09) | (0.06) | |
Cash per Share |
0.44 | 0.34 | 0.20 | 0.18 | |
Shareholders Equity per Share |
0.24 | 0.11 | 0.03 | 0.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.24 | 0.11 | 0.03 | 0.06 | |
Free Cash Flow |
(10.92) | (12.63) | (12.32) | (11.32) | |
Working Capital |
23.64 | 8.89 | 1.98 | 9.11 | |
Capital Expenditures |
(0.03) | (0.05) | (0.21) | (0.02) | |
Net Current Asset Value |
22.48 | 7.96 | 1.28 | 8.60 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.17 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.29 | 0.34 | 0.38 | 0.73 | |
Average Payables |
0.94 | 1.11 | 0.95 | 0.75 | |
Average Inventory |
0.57 | 0.35 | 0.48 | 0.49 | |
Average Assets |
37.90 | 35.58 | 33.44 | 38.81 | |
Average Common Equity |
(39.01) | (46.18) | (32.96) | (17.81) |
Columns are period end dates